Using AI to improve breast cancer treatment planning
Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer
This study is testing whether new artificial intelligence tools can help doctors make better treatment plans for breast cancer patients by improving how they analyze medical images and reports.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | Female |
| Sponsor | Instituto de Investigacion Sanitaria La Fe Academic / other |
| Locations | 8 sites (Buenos Aires and 7 other locations) |
| Trial ID | NCT05070884 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and validate artificial intelligence solutions that enhance the clinical deployment of radiomics tools for breast cancer. It focuses on creating reliable methods for precise diagnosis, treatment recommendations, and prognosis estimates based on radiological images and pathological reports. The study will assess the effectiveness of these AI tools in predicting treatment responses to neoadjuvant chemotherapy and evaluating residual disease. By integrating these solutions into clinical oncology, the study seeks to improve patient outcomes and streamline treatment planning.
Who should consider this trial
Good fit: Ideal candidates are females aged 18 to 85 who are referred for breast cancer diagnosis and have the necessary radiological and pathological data available.
Not a fit: Patients with incomplete or low-quality data may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to more accurate treatment planning and better outcomes for breast cancer patients.
How similar studies have performed: Other studies have shown promise in using AI for cancer treatment planning, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Females ≥ 18 years up to 85 years old * Individuals referred to hospitals for diagnosis of breast cancer * Availability of radiological images: 2D mammography or 2D synthetic digital tomosynthesis, ultrasound, or magnetic resonance * Availability of pathological report (surgical specimen) * Availability of (Neoadjuvant) treatment allocation (scheme, duration, benefit) * Availability of treatment response Exclusion Criteria: * Patient with incomplete or low-quality data (radiological, pathological or clinical)
Where this trial is running
Buenos Aires and 7 other locations
- Alexander Fleming — Buenos Aires, Argentina (Not_yet_recruiting)
- Medical University of Vienna — Vienna, Austria (Not_yet_recruiting)
- University of Zagreb School of Medicine — Zagreb, Croatia (Not_yet_recruiting)
- Ain Shams University — El Cairo, Egypt (Not_yet_recruiting)
- Medical University of Gdansk — Gdańsk, Poland (Not_yet_recruiting)
- Hospital Universitario y Politécnico La Fe de Valencia — Valencia, Spain (Recruiting)
- Karolinska Institute — Stockholm, Sweden (Not_yet_recruiting)
- Hacettepe University — Ankara, Turkey (Not_yet_recruiting)
Study contacts
- Study coordinator: Ana Penades-Blasco, M.Ec
- Email: ana_penades@iislafe.es
- Phone: +34 961245633
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.